Multi-Center, Open Label, Single Arm Phase IIIB Study on Safety and Efficacy of Subcutaneous Tocilizumab in Monotherapy or in Combination With Methotrexate or Other Non-Biologic Disease Modifying Antirheumatic Drugs in Rheumatoid Arthritis Patients With an Inadequate Response to Non-Biologic DMARDs - OSCAR
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms OSCAR; TOZURA
- Sponsors Roche
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
- 06 Apr 2018 Results (n=1804) of pooled data from 11 clinical trials assessing the efficacy, safety and immunogenicity of TCZ-SC 162 mg qw as monotherapy and in combination with csDMARDs over 24 weeks in adult patients with moderate to severe RA in a broad geographic setting, were published in the Rheumatology.
- 13 Dec 2017 Results (n=1804) of pooled analysis of TOZURA study programme of this and other ten studies assessing efficacy, safety and immunogenecity, published in the Rheumatology.